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Background: Bleeding events after SAVR are frequent and are associated with an unfavorable prognosis. However, there are no data from 
randomized studies concerning the incidence, predictors and impact of bleeding events on long-term prognosis after TAVR compared with SAVR.
Methods: From cohort B in the PARTNER Trial, 179 inoperable pts were randomly assigned to transfemoral (TF) TAVR. From cohort A, operable but 
high-risk pts were randomized to (TF) TAVR (244 pts) or SAVR (248 pts), and in those with inadequate transarterial access, pts were randomized to 
transapical (TA) TAVR (104 pts) or SAVR (103 pts). The Edwards-Sapien valve was used (23 or 26mm diameter), via either a large 22 or 24-Fr sheath 
(TF) or a 29-Fr dedicated delivery catheter system (TA). Major bleeding (MB) was defined according to a modified version of the VARC definition. 
Thirty-day MB rates, predictors and long-term impact on mortality were assessed.
Results: The 30-day MB rate in cohort A TF pts compared to cohort B TF pts was significantly lower (9.1% vs. 18.0% p=0.007). The rate of MB 
requiring at least 1 transfusion was also significantly lower in cohort A TF compared to cohort B TF (6.2% vs. 14.6%, p=0.004). Thirty-day MB 
in cohort A was similar between TA and TF but significantly lower than in SAVR pts (TAVR 9.3% vs. SAVR 19.5%, p<0.001). MB in cohort B TF pts 
was significantly associated with an increase in 1-year risk of mortality (HR: 2.27, 95%CI [1.31, 3.94], p=0.003) but not in cohort A TF or TA pts. 
However, MB in SAVR was strongly associated with an increased mortality risk at 1-year (HR: 2.82, 95%CI [1.86, 4.28], p<0.001. The only identifiable 
independent predictor of MB for the overall TF population (A and B) was enrollment in cohort B (HR:1.67, 95%CI [1.19, 3.5] p=0.03).
Conclusion: MB was significantly more frequent after SAVR than TAVR and MB events after SAVR were strongly associated with an increased risk of 
mortality at 1 year. The incidence, need for transfusion, and long-term impact of MB in the TF-TAVR pts decreased with lower patient risk profiles and 
increased operator experience at the enrolling sites.
